At a Glance
- Company: ErVimmune
- Location: Undisclosed (likely France/Europe biotech hub)
- Deal value: €17m Series A first closing
- Focus area: ErVac01 off-the-shelf cancer vaccine targeting HERV antigens
- Next steps: Initiate clinical development of lead asset
What happened?
ErVimmune announced a €17 million Series A first closing to fund entry into clinical development with lead candidate ErVac01, an off-the-shelf cancer vaccine targeting human endogenous retrovirus (HERV) antigens. The funding supports preclinical validation through phase 1/2 trials.
Why does it matter?
HERVs represent 8% of the human genome but are silenced in healthy cells and reactivated in many cancers (breast, ovarian, melanoma, prostate), offering tumour-selective targets. ErVac01’s multi-HERV approach could elicit broad T-cell responses across solid tumours, addressing limitations of personalised neoantigen vaccines.
Who’s behind it?
ErVimmune pioneers HERV-targeted immunotherapy using proprietary antigen discovery and vaccine platforms. Investors include life sciences VCs betting on novel cancer vaccine modalities post-checkpoint success.
How was it achieved?
Proceeds fund CMC, IND‑enabling studies, phase 1 trial execution and platform expansion. First closing leaves room for syndicate expansion targeting full €30–40m Series A.
What’s next?
Complete preclinical package for ErVac01, file IND/CTAs mid‑2026, dose first patients H2 2026. Parallel work on combination strategies with checkpoint inhibitors/PD1s.
What are people saying?
ErVimmune CEO highlighted HERVs as “universal cancer targets finally unlocked.” Lead investors noted Series A validates “next wave of off-the-shelf vaccines.”